Brian S. Posner
At a glance: Brian S. Posner is Director at Dyne Therapeutics (DYN). Their latest SEC Form 4, filed Oct 6, 2026, reported a purchase of $40K. On file: 8 purchase lines ($315K) and 3 sale lines ($145K).
Disclosed holdings: about $435K of DYN stock: 27,000 shares reported on their latest Form 4 (filed Oct 6, 2026), valued at the Nov 19, 2026 close of $16.12. This counts only DYN shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.
Director at Arch Capital Group Ltd. (ACGL); Director at Dyne Therapeutics, Inc. (DYN)
Purchase track record
Strong record. Based on 7 purchases with a full 90 days of price history.
Brian S. Posner's InsiderPrint
16 trades from SEC Form 4 filings, 2020 to 2026, drawn as one fingerprint.
Reading this print: Mostly buys, trading about 2 times a year, typically $38K a trade.
- Bump outward: a purchase (13)
- Dent inward: a sale (3)
- One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.
Insiders with a similar print
- Eric R. NewellCFO · EGBN · 98% match
- Adam H. StedhamPresident · OPNW · 98% match
- Avrohom J. KessGeneral Counsel · TRV · 98% match
- Lori A. WoodsDirector · CATX · 98% matchTheir buys since 2023: 3 of 3 beat the S&P 500
- David A. PeacockCEO · ADV · 98% matchTheir buys since 2023: 6 of 12 beat the S&P 500
Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.
Every purchase since 2020
From the SEC's insider data sets: each open-market buy by Brian S. Posner, matched to how the stock did over the next 90 days against the S&P 500.
2 of 4 buys beat the S&P 500 (50%), median +0.7% vs. the index. Small sample: treat with care. All insider buys: 46%.
| Stock | Filed | 90 days vs. S&P 500 |
|---|---|---|
| ACGL | Aug 4, 2025 | -10.8% |
| ACGL | Nov 1, 2022 | +10.8% |
| ACGL | May 2, 2022 | -3.1% |
| ACGL | May 20, 2020 | +4.4% |
Buys made close together in one stock count once. Price-only returns; history, not a prediction.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Oct 6SEC | DYNDyne Therapeutics, Inc.Before earningsPast buys 2/4 beat S&P | Buy | 2,50027,000 held (+10%) | $16.00 | $40K | +0.8% |
| Jun 9SEC | DYNDyne Therapeutics, Inc.Buy #4 in 60 daysPast buys 2/4 beat S&P | Buy | 2,00024,500 held (+9%) | $16.94 | $34K | -4.8% |
| Jun 5SEC | DYNDyne Therapeutics, Inc.Buy #3 in 60 daysPast buys 2/4 beat S&P | Buy | 2,50022,500 held (+12%) | $17.48 | $44K | -7.8% |
| Jun 4SEC | ACGLArch Capital Group Ltd. | Sell | 3,000 | $19.66 | $59K | — |
| May 28SEC | DYNDyne Therapeutics, Inc.Buy #3 in 60 daysPast buys 2/4 beat S&P | Buy | 2,00020,000 held (+11%) | $18.21 | $36K | -11.5% |
| May 22SEC | DYNDyne Therapeutics, Inc.Past buys 2/4 beat S&P | Buy | 2,50018,000 held (+16%) | $17.12 | $43K | -5.8% |
| May 12SEC | ACGLArch Capital Group Ltd. | Sell | 2,000 | $17.14 | $34K | — |
| Apr 1SEC | DYNDyne Therapeutics, Inc.First buyBuy #3 in 60 daysPast buys 2/4 beat S&P | Buy | 2,00015,500 held (+15%) | $17.08 | $34K | -5.6% |
| Mar 13SEC | DYNDyne Therapeutics, Inc.First buyPast buys 2/4 beat S&P | Buy | 2,00013,500 held (+17%) | $19.35 | $39K | -16.7% |
| Mar 12SEC | ACGLArch Capital Group Ltd. | Sell | 3,0002,000 held (−60%) | $17.11 | $51K | — |
| Mar 10SEC | DYNDyne Therapeutics, Inc.First buyPast buys 2/4 beat S&P | Buy | 3,00011,500 held (+35%) | $15.06 | $45K | +7.0% |
- Sell
Director Brian S Posner sold $51K of ACGL at $17.11 — cuts the stake by 60%.
- Buy
Director Brian S Posner bought $45K of DYN at $15.06 — first open-market purchase in our records; raises the stake by 35%.
Follow Brian S. Posner
Get one email when Brian S. Posner files a new purchase or sale. Free.
At most one email a day about Brian S. Posner, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.